Proteostasis dISRupted
Despite their importance, many crucial networks for protein quality control within cells diminish with age. The resulting loss of proteostasis, the process by which the health of a cell's proteins is monitored and maintained, is associated with a wide range of age-related human diseases. Costa-Mattioli and Walter review the integrated stress response (ISR), a central signaling network that responds to proteostasis defects by tuning protein synthesis. The ISR is activated in a wide range of pathological conditions, so a mechanistic understanding of its pathway may help in the development of therapeutic tools through which it can be modulated.
Science, this issue p. eaat5314
The integrated stress response (ISR) is an evolutionarily conserved intracellular signaling network that helps the cell, tissue, and organism to adapt to a variable environment and maintain health. In response to different environmental and pathological conditions, including protein homeostasis (proteostasis) defects, nutrient deprivation, viral infection, and oxidative stress, the ISR restores balance by reprogramming gene expression. The various stresses are sensed by four specialized kinases (PERK, GCN2, PKR and HRI) that converge on phosphorylation of a single serine on the eukaryotic translation initiation factor eIF2. eIF2 phosphorylation blocks the action of eIF2s guanine nucleotide exchange factor termed eIF2B, resulting in a general reduction in protein synthesis. Paradoxically, phosphorylation of eIF2 also triggers the translation of specific mRNAs, including key transcription factors, such as ATF4. These mRNAs contain short inhibitory upstream open reading frames in their 5-untranslated regions that prevent translation initiation at their canonical AUGs. By tuning down general mRNA translation and up-regulating the synthesis of a few proteins that drive a new transcriptional program, the ISR aims to maintain or reestablish physiological homeostasis. However, if the stress cannot be mitigated, the ISR triggers apoptosis to eliminate the damaged cell.
Our understanding of the central mechanisms that govern the ISR has advanced vastly. The ISRs central regulatory hub lies in the eIF2eIF2B complex, which controls the formation of the eIF2GTPmethionyl-intiator tRNA ternary complex (TC), a prerequisite for initiating new protein synthesis. Assembly of functional TC is inhibited by eIF2-P, which blocks eIF2B noncompetitively. In mammalian cells, the phosphorylation of eIF2 is a tightly regulated process. In addition to the four specialized eIF2 kinases that phosphorylate eIF2, two dedicated phosphatases antagonize this reaction. Both phosphatases contain a common catalytic core subunit, the protein phosphatase 1 (PP1), and a regulatory subunit (GADD34 or CReP), which render the phosphatase specific to eIF2. Structural and biophysical approaches have elucidated the mechanism of action of eIF2B and its modulation by ISR inhibitors and activators. Gene expression analyses have revealed complex ISR-driven reprogramming. Although it has been long recognized that, in the brain, long-term memory formation requires new protein synthesis, recent causal and convergent evidence across different species and model systems has shown that the ISR serves as a universal regulator of this process. Briefly, inhibition of the ISR enhances long-term memory formation, whereas activation of the ISR prevents it. Consistent with this notion, unbiased genome-wide association studies have identified mutations in key components of the ISR in humans with intellectual disability. Furthermore, age-related cognitive disorders are commonly associated with the activation of the ISR. Most notably, oxidative stress, misfolded proteins, and other stressors induce the ISR in several neurodegenerative disorders, including Alzheimers disease. Recent genetic and pharmacological evidence suggest that tuning the ISR reverses cognitive dysfunction as well as neurodegeneration in a wide range of memory disorders that result from protein homeostasis defects. Thus, long-term memory deficits may primarily result as a consequence of ISR activation rather than from the particular proteostasis defects that lead to its induction. Finally, the ISR is also implicated in the pathogenesis of a plethora of other complex diseases, including cancer, diabetes, and metabolic disorders.
The ISR is emerging as a central regulator of protein homeostasis at both the cellular and organismal level. Mechanistically, much remains to be understood regarding additional inputs into the eIF2BeIF2 regulatory hub controlling TC concentration, as well as the IRSs connectivity to other intracellular signaling networks. As yet, little is known about the role of the specific proteins whose synthesis is altered during acute and persistent ISR activation and how these effectors collaborate to compute the life or death decisions cells make upon ISR activation. ISR gene expression signatures and functional consequences will need to be mapped across different tissues, cell types, and developmental stages. In addition, it will be invaluable to generate additional genetic and molecular tools that permit the direct temporal and spatial manipulation of ISR pathway in specific cells and circuits to determine their function. From a medical perspective, the ISR is implicated in the etiology of several disorders, and manipulation of the ISR is emerging as a promising therapeutic avenue for the treatment of a variety of diseases. The use of innovative mouse models, patient-derived induced pluripotent stem cells, and human organoids will greatly enhance our ability to explore the ISRs clinical relevance further and help define therapeutic windows in which ISR modulation may prove beneficial. Identifying additional specific small-molecule inhibitors and activators of the ISR will offer valuable opportunities to dissect the role of the ISR pharmacologically in health and disease. Finally, discovery and mechanistic understanding of additional ISR modulators will increase the repertoire of therapeutic targets and may further enable clinical development in a wide range of age-related human diseases.
Diverse deviations from homeostasis activate the ISR. The resulting dysregulation of translation contributes to numerous diseases.
Protein quality control is essential for the proper function of cells and the organisms that they make up. The resulting loss of proteostasis, the processes by which the health of the cells proteins is monitored and maintained at homeostasis, is associated with a wide range of age-related human diseases. Here, we highlight how the integrated stress response (ISR), a central signaling network that responds to proteostasis defects by tuning protein synthesis rates, impedes the formation of long-term memory. In addition, we address how dysregulated ISR signaling contributes to the pathogenesis of complex diseases, including cognitive disorders, neurodegeneration, cancer, diabetes, and metabolic disorders. The development of tools through which the ISR can be modulated promises to uncover new avenues to diminish pathologies resulting from it for clinical benefit.
See the original post:
The integrated stress response: From mechanism to disease - Science Magazine
- Automated iPS Cell Production to Start in Japan in April - Nippon.com - January 9th, 2025
- iPSCs: take the survey and win! - RegMedNet - January 9th, 2025
- Automated iPS cell production to start in Japan in April - The Japan Times - January 9th, 2025
- Dysregulation of mTOR signalling is a converging mechanism in lissencephaly - Nature.com - January 1st, 2025
- BrightPath-Cellistic partner for clinical trial advancements of CAR-T cell therapy - Yahoo Finance - December 17th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 15th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 13th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 7th, 2024
- What are Induced Pluripotent Stem Cells? | ISCRM - December 7th, 2024
- Induced pluripotent stem cells, a giant leap for mankind therapeutic ... - December 7th, 2024
- Advantages and disadvantages of induced pluripotent stem cells - December 7th, 2024
- Generation and long-term culture of human cerebellar organoids from pluripotent stem cells - Nature.com - December 3rd, 2024
- Whats the secret to living to 100? Centenarian stem cells could offer clues - Nature.com - December 1st, 2024
- Single-cell RNA sequencing reveals key regulators and differentiation trajectory of iPSC-derived cardiomyocytes - Nature.com - November 26th, 2024
- Cell therapy weekly: GMP certification of iPSC-focused manufacturing facility - RegMedNet - November 25th, 2024
- Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - Pharmaceutical Technology - November 22nd, 2024
- Alloy Therapeutics, Takeda Partner on Revolutionary iPSC Cell Therapy Platform | TAK Stock News - StockTitan - November 22nd, 2024
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections - The Japan News - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Monthly information on share capital and company voting rights - July 5th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
Recent Comments